Bevacizumab (Avastin).
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005252:Fees, Pharmaceutical; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous / Q000191:economics; D007680:Kidney Neoplasms / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab